

[Get Access](#)[Share](#)[Export](#)

Journal of the National Medical Association

Volume 102, Issue 6, June 2010, Pages 511-525

Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?

Thaddeus J. Bell MD¹ ... Eugene E. Wright Jr. MD²  

 [Show more](#)

[https://doi.org/10.1016/S0027-9684\(15\)30560-5](https://doi.org/10.1016/S0027-9684(15)30560-5)

[Get rights and content](#)

Type 2 diabetes poses a major health challenge among African Americans. Older therapies are associated with shortcomings such as hypoglycemia and/or weight gain. In recent years the "incretin system" has become understood as offering great promise for drug development. Two drug classes—namely, the injectable glucagon-like peptide 1 (GLP-1) receptor agonists, which produce pharmacological GLP receptor activity, and the oral dipeptidyl peptidase-4 (DPP-4) inhibitors, which raise levels of endogenously produced GLP-1 and glucose-dependent insulintropic polypeptide (GIP) by preventing enzymatic degradation—have been available for several years. These drugs can be given as monotherapy or added to other antidiabetic drugs to lower blood glucose with very low risk of hypoglycemia without weight gain. In fact, GLP-1 receptor agonists may induce clinically significant reductions in weight and systolic blood pressure, as well as improve indices of B-cell function. Although transient nausea occurs in some patients with GLP-1 receptor agonists, these agents are generally well tolerated, and the available clinical data are encouraging. Clinical experience shows that these treatments are acceptable to patients.

[Previous](#)[Next](#)

Keywords

diabetes; African Americans

[Recommended articles](#)[Citing articles \(5\)](#)

Funding/support: Dr Bell has no conflicts of interest to report. Dr Wright has been a consultant and has participated in speakers' bureaus for Amylin-Lilly.

Copyright © 2010 National Medical Association. Published by Elsevier Inc. All rights reserved.

ELSEVIER

[About ScienceDirect](#) [Remote access](#) [Shopping cart](#) [Contact and support](#) [Terms and conditions](#) [Privacy policy](#)

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [use of cookies](#).

Copyright © 2018 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

 RELX Group™